References
1. Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American
Psychiatric Association. 1992.
2. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly
common disorder. Neurotherapeutics. 2014;11(1):166-176. doi:10.1007/s13311-013-0222-5
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.,
text revision. American Psychiatric Association; 2023.
4. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental
Health; 1976.
5. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic
drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148, viii.
doi:10.1016/j.ncl.2010.10.002
6. Kenney C, Hunter C, Davidson A, Jankovic J. Metaclopramide, an increasingly recognized cause
of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-384. doi:10.1177/0091270007312258
7. Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and
the implications for future research. Front. Pharmacol. 2018;9:913. doi:10.3389/fphar.2018.00913
8. Data on file. Neurocrine Biosciences, Inc.
9. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of
second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278.
doi: 10.4088/JCP.16r10832
10. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-
year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin
Psychiatry. 2008;69(10):1580-1588. doi:10.4088/jcp.v69n1008
11. National Alliance for Mental Illness. Mental health by the numbers. Accessed January 27, 2021.
https://www.nami.org/learn-more/mental-health-by-the-numbers
12. Reinert M, Fritze D, Nguyen T. The state of mental health in America 2023. Mental Health
America; 2022.
13. Boumans CE, de Mooij KJ, Koch PA, van ‘t Hof MA, Zitman FG. Is the social acceptability of
psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344.
doi:10.1093/schbul/20.2.339
14. Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions.
Acta Psychiatr Scand. 1989;80(1):64-67. doi:10.1111/j.1600-0447.1989.tb01301.x.
15. Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci.
2017;383:199-204. doi:10.1016/j.jns.2017.11.019